Alector, Inc. ALEC
We take great care to ensure that the data presented and summarized in this overview for Alector, Inc. is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding ALEC
View all-
Black Rock Inc. New York, NY9.1MShares$20.1 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA5.46MShares$12.1 Million0.0% of portfolio
-
Deep Track Capital, LP Greenwich, CT4.63MShares$10.2 Million0.8% of portfolio
-
Morgan Stanley New York, NY4.36MShares$9.63 Million0.0% of portfolio
-
Jpmorgan Chase & CO New York, NY2.73MShares$6.03 Million0.0% of portfolio
-
State Street Corp Boston, MA2.62MShares$5.78 Million0.0% of portfolio
-
Braidwell LP Stamford, CT2.16MShares$4.77 Million0.29% of portfolio
-
Geode Capital Management, LLC Boston, MA1.9MShares$4.21 Million0.0% of portfolio
-
Euclidean Capital LLC New York, NY1.31MShares$2.89 Million0.67% of portfolio
-
Soleus Capital Management, L.P. Greenwich, CT1.21MShares$2.67 Million0.48% of portfolio
Latest Institutional Activity in ALEC
Top Purchases
Top Sells
About ALEC
Alector, Inc., a clinical stage biopharmaceutical company, develops therapies for the treatment of neurodegeneration diseases. Its products include AL001, a humanized recombinant monoclonal antibody, which is in Phase III clinical trial for the treatment of frontotemporal dementia, Alzheimer's, Parkinson's, and amyotrophic lateral sclerosis diseases; and AL101 that is in Phase I clinical trial for the treatment of neurodegenerative diseases, including Alzheimer's and Parkinson's diseases. The company also offers AL002, a product candidate that is in Phase II clinical trial for the treatment of Alzheimer's disease; and AL003, which is in Phase I clinical trial for the treatment of Alzheimer's disease. In addition, its products in development stage include AL044 that targets MS4A4A, a risk gene for Alzheimer's disease. Alector, Inc. has a collaboration agreement with Adimab, LLC for the research and development of antibodies; and a strategic collaboration agreement with GlaxoSmithKline plc for the development and commercialization of monoclonal antibodies, such as AL001 and AL101 to treat neurodegenerative diseases. The company was founded in 2013 and is headquartered in South San Francisco, California.
Insider Transactions at ALEC
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Dec 02
2024
|
Gary Romano Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
14,892
-4.09%
|
$29,784
$2.52 P/Share
|
|
Dec 02
2024
|
Sara Kenkare Mitra President and Head of R&D |
SELL
Open market or private sale
|
Direct |
26,500
-4.48%
|
$53,000
$2.52 P/Share
|
|
Dec 02
2024
|
Arnon Rosenthal Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
52,172
-2.04%
|
$104,344
$2.52 P/Share
|
|
Dec 02
2024
|
Marc Grasso Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
16,489
-4.75%
|
$32,978
$2.52 P/Share
|
|
Oct 01
2024
|
Gary Romano Chief Medical Officer |
BUY
Grant, award, or other acquisition
|
Direct |
184,380
+33.61%
|
-
|
|
Oct 01
2024
|
Arnon Rosenthal Chief Executive Officer |
BUY
Grant, award, or other acquisition
|
Direct |
610,500
+19.26%
|
-
|
|
Oct 01
2024
|
Sara Kenkare Mitra President and Head of R&D |
BUY
Grant, award, or other acquisition
|
Direct |
300,000
+33.64%
|
-
|
|
Oct 01
2024
|
Marc Grasso Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
216,400
+38.4%
|
-
|
|
Sep 03
2024
|
Marc Grasso Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
7,297
-5.29%
|
$29,188
$4.88 P/Share
|
|
Sep 03
2024
|
Gary Romano Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
8,478
-4.5%
|
$33,912
$4.88 P/Share
|
|
Sep 03
2024
|
Sara Kenkare Mitra President and Head of R&D |
SELL
Open market or private sale
|
Direct |
13,926
-4.56%
|
$55,704
$4.88 P/Share
|
|
Sep 03
2024
|
Arnon Rosenthal Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
26,499
-1.34%
|
$105,996
$4.88 P/Share
|
|
Aug 22
2024
|
Richard H Scheller |
SELL
Open market or private sale
|
Direct |
44,250
-55.84%
|
$221,250
$5.16 P/Share
|
|
Aug 12
2024
|
Kristine Yaffe |
SELL
Open market or private sale
|
Direct |
5,000
-6.88%
|
$25,000
$5.06 P/Share
|
|
Aug 12
2024
|
Paula Hammond |
SELL
Open market or private sale
|
Direct |
10,500
-14.85%
|
$52,500
$5.06 P/Share
|
|
Aug 02
2024
|
Richard H Scheller |
BUY
Grant, award, or other acquisition
|
Direct |
15,833
+23.75%
|
-
|
|
Jun 12
2024
|
Paula Hammond |
BUY
Grant, award, or other acquisition
|
Direct |
35,000
+33.11%
|
-
|
|
Jun 12
2024
|
David M. Wehner |
BUY
Grant, award, or other acquisition
|
Direct |
35,000
+23.28%
|
-
|
|
Jun 12
2024
|
Richard H Scheller |
BUY
Grant, award, or other acquisition
|
Direct |
35,000
+30.63%
|
-
|
|
Jun 12
2024
|
Elizabeth A. Garofalo |
BUY
Grant, award, or other acquisition
|
Direct |
35,000
+36.36%
|
-
|
Last 12 Months Summary
| Grant, award, or other acquisition | 1.62M shares |
|---|---|
| Other acquisition or disposition | 197K shares |
| Open market or private sale | 320K shares |
|---|---|
| Other acquisition or disposition | 1.2M shares |